Definitive Healthcare Corp. (NASDAQ:DH) Given Consensus Recommendation of “Reduce” by Brokerages

Definitive Healthcare Corp. (NASDAQ:DH) has received an average recommendation of “Reduce” from the nine ratings firms that are presently covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a sell rating, three have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $2.4714.

A number of equities research analysts have issued reports on the company. Zacks Research upgraded Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 28th. Robert W. Baird set a $1.10 price objective on shares of Definitive Healthcare in a research note on Friday, May 8th. Bank of America restated an “underperform” rating and set a $0.70 target price on shares of Definitive Healthcare in a research report on Monday, June 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Definitive Healthcare in a report on Wednesday, June 3rd. Finally, Wall Street Zen upgraded shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a research report on Sunday, July 26th.

Definitive Healthcare Stock Performance

Shares of DH stock opened at $0.68 on Monday. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.81. Definitive Healthcare has a 12-month low of $0.62 and a 12-month high of $4.70. The stock has a market capitalization of $72.00 million, a P/E ratio of -0.42, a P/E/G ratio of 11.01 and a beta of 1.35. The firm’s 50 day moving average is $0.80 and its 200 day moving average is $1.18.

Definitive Healthcare (NASDAQ:DH) last announced its earnings results on Thursday, May 7th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The business had revenue of $55.93 million during the quarter, compared to analyst estimates of $55.02 million. Definitive Healthcare had a negative net margin of 76.04% and a positive return on equity of 4.04%. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. Research analysts expect that Definitive Healthcare will post 0.04 earnings per share for the current year.

Institutional Investors Weigh In On Definitive Healthcare

Several hedge funds and other institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC lifted its position in Definitive Healthcare by 56.7% during the first quarter. AQR Capital Management LLC now owns 590,149 shares of the company’s stock valued at $1,706,000 after purchasing an additional 213,562 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Definitive Healthcare by 564.2% during the first quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock valued at $25,191,000 after purchasing an additional 7,404,363 shares during the period. Jane Street Group LLC increased its position in Definitive Healthcare by 166.0% in the first quarter. Jane Street Group LLC now owns 105,114 shares of the company’s stock worth $304,000 after buying an additional 65,597 shares in the last quarter. Creative Planning raised its stake in shares of Definitive Healthcare by 41.7% in the second quarter. Creative Planning now owns 28,628 shares of the company’s stock worth $112,000 after buying an additional 8,428 shares during the period. Finally, Arrowstreet Capital Limited Partnership purchased a new position in shares of Definitive Healthcare during the 2nd quarter valued at about $4,247,000. 98.67% of the stock is currently owned by hedge funds and other institutional investors.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.